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Two simple, rapid, and sensitive spectrophotometric methods are proposed for the determination of levodopa (LD). The ﬁrst
methodisbasedoncouplingof4-aminoantipyrine(4-AAP)withoneofthedopaminederivatives(LD,CD)togiveanewligandthat
reactswithcoppertetraminecomplextogiveintenselycoloredchelates.Thecoloredproductsarequantiﬁedspectrophotometrically
at 525 and 520nm for LD and CD, respectively. The optimization of the experimental conditions is described. The method has been
used for the determination of 19.7–69.0a n d1 8 .1–54.3µgm L −1 of LD and CD, respectively. The accuracy of the method is achieved
by the values of recovery (100 ± 0.2%) and the precision is supported by the low standard deviation (SD = 0.17–0.59) and relative
standard deviation (CV = 0.4%–1.54%) values. The second method is based on the formation of ion-pair iodinated inner sphere or
outer sphere colored complexes between the LD and triiodide ions at pH 5 and room temperature (23±3◦C). This method has been
used for the determination of LD within the concentration range 39.44–78.88µgm L −1 with SD = 0.22–0.24 and recovery percent
= 100 ± 0.3%. The sensitivity of the two methods is indicated by Sandell’s sensitivity of 0.014–0.019g cm−2. The results of the two
methods are compared with those of the oﬃcial method. The interference of common drug additives, degradation products, and
excipients was also studied. The proposed methods were applied successfully to the determination of the LD-CD synthetic mixture
and Levocare drug. The determination of LD in urine of some schizophrenic patients was applied with good precision and accuracy.
The reliability of the methods was established by parallel determinations against the oﬃcial British pharmacopoeia method.
INTRODUCTION
Thedopaminederivativesparticipateintheregulation
of a wide variety of physiological functions in the human
body and in medication life depending on their structures
(Figure 1).
Hormones act as chemical messengers controlling
the activity of living things. They are released in small
amounts in the blood stream from a number of vi-
tal sites especially some brain regions. Dopamine was
recognized as a neurotrasmitter in its own right but
the demonstration of its nonuniform distribution in the
brain suggested that it might have a speciﬁc functional
role of dopamine [1]. It had an important role in the
pathogenesis of drug treatment of certain brain diseases,
Parkinson’s disease, and schizophrenia. Parkinson’s dis-
ease was associated with decrease of dopamine concen-
tration in the brain (Nozaki Y, Abe T, Takahashi S,
1995), [2]. So it must be medicated with drugs contain-
ing LD combined with a certain amount of CD, which
makes LD available for transport to the brain and con-
verted to dopamine in the basal ganglia [3, 4]. The brain
of a schizophrenic patients produces more dopamine,
especially in the striatum of the brain, than the nor-
mal brain (see http://serendip.brynmawr.edu/bb/neuro/
neuro98/202s98-paper1/Frederickson.html). In this case,
the drug used blocks dopamine receptors in the brain.
The increasing awareness of the biological signiﬁcance of
dopamine derivatives has promoted a great deal of re-
search into their detection and quantitative determina-
tion [5, 6] (Stores W, Putters J, Van Rijn HJM, 1987).
Several methods have been described in the literature for
dopamine determination in biological samples and phar-
maceutical formulation like chromatography and amper-
ometry [7, 8]. Ratiospectra derivative spectrophotometry
procedure was applied on detection of binary mixtures of2 F. A. Nour El-Dien et al 2005:1 (2005)
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Figure 1. Structural formulae of the investigated dopamines.
LD and benserazide in their pharmaceutical preparations
as well as other compounds frequently associated with
them [9]. Many hospital laboratories are now adopting
the HPLC method for measuring catecholamines (Musso
NR, Vergassola C, Pende A, Lotti G, 1990), (Kitahashi T,
Ohba Y, Sawada Y, Suzuki H, 1991) [10, 11]. However,
HPLC technique is very time-consuming and restricted to
the highly specialized, so many spectrophotometric pro-
cedures were recommended for dopamine detection us-
ing ninhydrin (Biryuk LA, Petrenko VV, Zorya BP, 1992)
and chloramine-T (Nagaraja P, Murthy KCS, Yathirajan
HS, Mohan BB, 1998).
The purpose of the present work is to describe the de-
velopmentoftwosimple,sensitive,andrapidspectropho-
tometric methods for the determination of LD, CD, and
α-MD depending upon the formation of their colored
copper mixed ligand chelates and colored ion-pair outer
sphere and/or inner sphere iodinated compounds with
triiodide ion. Diﬀerent experimental conditions are care-
fully studied before applying Beer’s law. The two meth-
ods were applied for determining dopamine derivatives in
pure, pharmaceutical, and urine samples.
EXPERIMENTAL
Apparatus
All absorption spectra measurements were recorded
using a Milton Roy Spectronic 601 and an automated
Perkin Elmer Lambda 20 UV/Vis spectrophotometer in
the wavelength range 200–900nm. The pH adjustment
was done using a Titrino Metrohm 716 DMS, connected
to a Metrohm stirrer. This instrument has a combined
glass and reference electrodes used for pH measurements.
For selecting accurate microliter volumes, the calibrated
micro-pipette (BRAND) of disposable plastic tips was
used in the range 100–1000µL.
Materials
All reagents were of the analytical grade. LD and CD
were purchased from El-Naser Pharmaceutical Company.
The 4-AAP was obtained from Fluka Chemie AG. Copper
sulphate (CuSO4.5H2O) was purchased from Sigma, io-
dine and potassium iodide, ammonia solution 33% (v/v),
and sodium hydroxide were supplied from BDH. Glacial
acetic acid, boric acid and phosphoric acid (90%) were
purchased from Aldrich.
Reagents
10−2 M stock solutions of LD and CD were prepared
in deionized water. 10−3 M solutions of these drugs were
obtainedbyaccuratedilution.Alldopaminederivativeso-
lutions were stored in dark bottles at 4◦Ci nt h er e f r i g e r a -
tor to avoid their oxidation [12]. 10−2–10−3 M solutions
of copper sulphate were obtained by accurate dilution
from 0.1M acidiﬁed stock solution (0.3mLH 2SO4) that
standardized by recommended procedure (Yoe, Jones,
1944). The ammonia solution of 3.5M and universal
buﬀer of acetic, boric, and phosphoric acids (0.04M of
each in one liter mixture of various pH values) were used
for pH adjustment of the drug reagents reaction media.
0.1M solutions of interfering materials (glucose, maltose,
2-nitrophenol, pyrogallol, resorcinol, pyrocatechol, urea,
salicylic acid, paracetamol, and ascorbic acid) were pre-
pared by dissolving appropriate weight in 25mL deion-
ized water. The 10−2–10−3 M solutions of the interfering
materials were prepared by accurate dilution from the
stock solution.
Procedures
(I) An aliquot containing 19.7–69 or 18.1–
54.3µgm L −1 of LD or CD, respectively, was transferred
to a 10mL measuring ﬂask, followed by 0.3mL from
10−2 M copper sulphate mixed with 0.24mL of 3.5M
ammonia to have pH 10.5a n d0 .2mLof0.0295M 4-AAP.
The blue to violet color mixture was completed to 10mL.
The mixtures were shaken well and allowed to stand at
22 ± 3◦C for 10 and 12 minutes, and the absorbance was
measured at 525 and 520nm against deionized water
as a blank for LD and CD, respectively. The calibration
curves were obtained applying the same procedure using
standard drug solutions.
(II) An aliquot containing 39–79µgm L −1 of LD was
transferred to a 10mL measuring ﬂask, followed by addi-
tion of 0.1mLof0.1MI
−
3 reagent and universal buﬀer of
pH 5 up to the mark. The mixture was shaken well and al-
lowed to stand for 6minutes at 23 ±2◦C. The absorbance
of the colored reaction product was measured at 500nm.
The calibration curve for LD was obtained applying the
same procedure using standard drug solutions.
Analysisofdosageforms
The contents of tablets of Levocare, for LD (250mg),
were weighed, powdered, and then transferred to a
100mL beaker containing 50mL of deionized water. The
solution was ﬁltered in Whatman No 1 ﬁlter paper,
washedwell,andtheﬁltratewastransferredintoa100mL
volumetric ﬂask and completed to the mark. An aliquot
of the solution containing 50µgm L −1 of the analyte was
transferred to a 10mL measuring ﬂask and analyzed ap-
plying either procedure (I) or procedure (II).2005:1 (2005) Assays for Dopamine Derivatives 3
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Figure 2. Coupling reaction between phenyl and 4-AAP.
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AnalysisofsyntheticmixtureofLDandCD
An aliquot of a synthetic mixture of LD and CD in
a ratio of 10 : 1, as that found in Levocare drug tablets,
was analyzed for LD by applying procedures (I) and (II)
to detect what the eﬀe c to fC Di so nL Dd e t e r m i n a t i o n .
Urineanalysis
The urine samples were collected from 6 normal peo-
pleand5schizophrenicpatientsandtransferredintowell-
cleaned sample tubes. To 20mL urine samples, one drop
of 3N HCl was added to get a ﬁnal pH of 3, and a rapid
centrifuge for 30seconds must be done to get homogene-
ity of the sample. The urine samples of schizophrenic pa-
tients were analyzed for LD in comparison with normal
ones.
RESULTS AND DISCUSSION
The theory of drug reactions with reagents is illus-
trated as follows.
Inprocedure(I)
Diﬀerent colorimetric methods described for phe-
nol determination (Emerson E, 1943), (Chen Y, Wang
S, Zhou T, 1998), (Frank M, Matthias O, 1995), [13, 14]
are based on the reaction between phenols and 4-AAP to
formantipyrinedyeswhere4-AAPisfoundtobethemost
sensitive, fast, and precise colorimetric reagent. 4-AAP re-
actswithphenolic-typecompoundsaccordingtothereac-
tion shown in Figure 2. The reaction product may be any
color from red to purple depending on the phenolic-type
compounds involved.
Applying the molar ratio method, it is found that cat-
echolamines form a dye-coupled product with 4-AAP in
the ratio 1 : 1 Cu : dye products. The reaction may pro-
ceed as given in Scheme 1:
Cu2+ +4 NH 3 

Cu(NH3)4
2+. (1)
The solid products of this reaction are separated and
characterized using diﬀerent tools like elemental analysis,
IR, magnetic, UV-Vis and thermal analysis and recently
published [15].
Inprocedure(II)
Iodine in iodide medium forms two species in equi-
librium to each other:
I− +I 2  I−
3 . (2)
Iodine is amphoteric in nature, that is, it can act as an
electron donor or acceptor due to its molecular orbital
structure [16, 17]. The phenolic groups of dopamine may
be oxidized and iodinated with iodine which acts as an
electron acceptor due to the following reaction:
R1R2L(OH)2 +2 I 2  R1R2L(OI)2 +2HI (3)4 F. A. Nour El-Dien et al 2005:1 (2005)
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I
−
3 can react with LD by formation of inner and/or outer
sphere complexes [17] as shown in Scheme 2.
The separated iodinated solid products were investi-
gatedusingdiﬀerenttoolsandtheresultsareunderprepa-
ration for publication.
DeterminationofLDandCDusingCu(II)
complexand4-AAP
Optimum conditions aﬀecting the reaction of LD and
CDwithCu(II)tetraminecomplexand4-AAPwerestud-
ied carefully. The eﬀect of pH was studied in the pH
rangeof9.5–12usingammoniasolution(3.5M)asshown
in Figure 3. From the data it was found that the pH of
10.5 is the most suitable for microdetermination of the
drugs where the complex is formed without any turbid-
ity and it gave the highest absorbance. The stoichiometric
ratio was performed using the molar ratio method and
it was found to be 1 : 1 : 1 Cu+2 : 4-AAP : drug (Issa
and Amin, 1996). Figure 4 shows the eﬀect of time on
the reaction of dopamine derivatives using procedure (I).
The time needed for complete formation of metal com-
plexes is 10 and 12 minutes to develop its maximum ab-
sorbance at room temperature (23 ± 2◦C) in case of LD
and CD, respectively. The sequence of addition was stud-
ied and found to have the order Cu (II) tetramine com-
plex, dopamine derivative, and then 4-AAP.
Under optimum conditions, a correlation was ob-
tained between absorbance (A) and the concentration (C)
over the range 19.7–69.0a n d1 8 .1–54.3µgm L −1 of LD
and CD, respectively. The apparent molar absorptivity,
Sandell sensitivity, standard deviation (SD), and coeﬃ-
cient of variation (CV) for each drug are tabulated in
Table 1. The apparent molar absorptivity of the result-
ing colored products was found to be 2.4 × 103 and
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Figure 3. Clustered column showing relation between pH and
absorbance in case of (a) LD-copper (II) complex and (b) CD-
copper (II) complex.
1.7 × 103 Lm o l −1 cm−1, whereas Sandell sensitivities are
0.014 and 0.019g cm−2 for LD and CD, respectively. The
correlation coeﬃcient was found to be 0.999 and 0.995,2005:1 (2005) Assays for Dopamine Derivatives 5
Table 1. Statistics for the recovery of LD and CD with copper (II) complex and 4-AAP, and LD with I
−
3 .
Parameters
LD CD LD
(procedure (I)) (procedure (I)) (procedure (II))
Detection range (µg/mL) 19.72–69.02 18.1–54.33 9 .44–78.88
Correlation coeﬃcient 0.999 0.995 0.999
Sandell sensitivity 0.014 0.019 0.026
Molar absorptivity
(L mol−1cm−1) 2.4×103 1.8×103 5.1×103
SD 0.174 0.256 0.239
CV (%) 0.89 0.68 0.54
Number of replicates υ1 3.03 .03 .0
Number of replicates υ2 4.03 .03 .0
Ft e s t 6 .58 7.07 6.78
F∗ test 6.59 9.28 9.28
Number of replicates υ1 9.04 .04 .0
t test 0.565 0.191 0.865
t∗ test 2.262 2.776 2.776
F∗ test is the values for V as degree of freedom for various conﬁdence levels.
t∗ test is the values for V as degree of freedom for 95% conﬁdence level.
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Figure 4. Eﬀect of time on the absorbance of (a) LD and (b) CD
with copper tetramine and 4-AAP.
while the SD is 0.174 and 0.256 for LD and CD, respec-
tively. The low values of CV and SD indicate the high
accuracy, precision, and reproducibility of the proposed
method to determine dopamine derivatives.
DeterminationofLDusingI
−
3 ionasoxidizingagent
Theprincipleunderlyingthedeterminationoftheim-
portant compound LD depends upon the reactions with
iodine-triiodide under proper conditions (Scheme 2).
The produced colored compound is investigated photo-
metrically. This work involves the study of these color re-
actions to obtain the stoichiometric ratio of the reactants
and optimum conditions to develop the best color and to
select the suitable wavelength for microdetermination of
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Figure 5. Clustered column showing relation between pH and
absorbance in case of LD with iodine compound at wavelength
= 500nm.
LD. The low oxidation potential of the iodine reaction
makes it much more selective than the other oxidizing
agents [17].
The selected optimum pH using universal buﬀer
(pH range 2–12) is 5 at maximum wavelength 500nm
(Figure 5). The most suitable ratio of [I
−
3 ] : [LD] was
found to be 3 : 2. The required time for the com-
pleteness of the reaction between the I
−
3 ion and LD
was found to be 6 minutes (Figure 6)w h i c hi ss u ﬃcient
where the absorbance is maximal and remains constant.
The eﬀect of temperature was studied in the tempera-
ture range 10–60◦C( Figure 7) and it was found that, for6 F. A. Nour El-Dien et al 2005:1 (2005)
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Figure 6. Eﬀect of time on the absorbance of LD-iodine com-
pound, at pH = 5 and at wavelength = 500nm.
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Figure 7. Eﬀect of temperature on the absorbance of LD-iodine
compound at wavelength = 500nm.
microdetermination of LD, it is preferable to adjust the
temperature at (23 ± 2◦C). LD can be determined in the
concentration range of 39.44–78.88µgm L −1. The stan-
darddeviationandrelativestandarddeviationvalueswere
foundtobe0.239%and0.54%,respectively(Table 1).The
apparent molar absorptivity and Sandell sensitivity of the
resulting colored product were found to be 5.1 × 103 and
0.026g cm−2, respectively. The values of these parameters
(Table 1) can be considered satisfactory at least for the
drugs concentration levels examined.
Interference
Several pharmaceutical preparations are associated
with ﬂavoring agents, diluents and excipients. Table 2
shows the eﬀect of organic interfering materials that may
b ep r e s e n ti np h a r m a c e u t i c a lp r e p a r a t i o n ss u c ha sg l u -
cose, maltose, 2-nitrophenol, phenol, pyrogallol, resorci-
nol, and pyrocatechol on the reaction of Cu (II) com-
plex and 4-AAP and on the reaction of I
−
3 with LD.
It was observed that glucose and maltose as carbohy-
drates are slightly interfered with when each of them is
present in 10-folds in the solution mixture. Therefore
tablet ﬁllers such as glucose and maltose, which can rep-
resent a source of interference in other methods, do not
interfere in the proposed method. Other interfering ma-
terials (2-nitrophenol, phenol, pyrogallol, resorcinol, and
pyrocatechol)werefoundtohaveinterferingeﬀects.Since
LD as a catecholamine is present in urine samples, the ef-
fectsofdiﬀerentinterferingmaterials(suchasurea,parac-
etamol, ascorbic acid, and salicylic acid) were tested dur-
ing microdetermination of LD using our proposed proce-
dure (Table 3). It was obvious that the equimolar amount
from urea or 1 fold of salicylic or ascorbic acid has a slight
interferencethatcanbeneglected,andthemixtureofurea
and salicylic acid showed slight error in percent recovery
forLD.Whereas,withparacetamolor10foldsfromascor-
bicacidshowinghighinterferencewithhighpercenterror
in detection.
DeterminationofLDinLD-CDsyntheticmixtures
In order to prove the applicability to determine LD in
some pharmaceutical forms like Levocare, synthetic mix-
tures containing LD and CD were prepared and analyzed
for LD determination (procedures (I) and (II)). In these
mixtures, the percent recovery of LD ranged from 94% to
98.8%.Thesedatareﬂectthehighavailabilityofthesepro-
cedures for microdetermination of LD in presence of CD.
From the data it is observed that procedure (II) is highly
selective for LD microdetermination in Levocare where it
gives percent error of 0.91%.
DeterminationofLDinpharmaceuticalforms
The proposed methods were applied satisfactorily to
the determination of LD in pharmaceutical preparation.
Levocare drug contains 250mg LD and 25mg CD in each
tablet as an active material. The determination of LD is
applied using both methods (Table 4) with percent errors
of 4.4% and 0.91% for methods (I) and (II), respectively,
that can be neglected where present within the interna-
tionally acceptable range of errors for pharmaceutical de-
termination.
DeterminationofLDinbiologicalsamples
Urine and blood samples of normal and abnormal
people usually contain many catecholamines. The biolog-
ical samples are very sensitive and must be collected and
stored under optimum conditions to prevent any loss of
catecholamines or change its nature [18]. LD is one of
the important catecholamine derivatives that can be de-
tected in the urine samples of schizophrenic patients be-
cause of its high concentration. Therefore LD concentra-
tion was determined in urine of normal and permanently
schizophrenic subjects using copper (II) complex and
4-AAP for the sake of comparison. The schizophrenic
patients’ samples are characterized by high availability2005:1 (2005) Assays for Dopamine Derivatives 7
Table 2. Tolerance oforganiccompounds inspectrophotometric determination of LD. [LD] = 2×10−4 M,[Cu(II)] = 0.1M,[4-AAP]
= 0.0295M, [I
−
3 ] = 0.1M, [tolerance] = 2 ×10−4 M (1-fold) and 2 ×10−3 M (10-fold), pH = 10.5, t = 10minutes and λ = 525nm.
Organic
tolerant
added
Fold
Absorbance Procedure (I) Procedure (II)
Procedures
Taken
(µg\mL)
Found
(µg\mL) Recovery % Taken
(µg\mL)
Found
(µg\mL) Recovery %
(I) (II)
—— 0 .69 0.64 39.44 39.51 100.25 9 .16 60.06 101.5
Glucose 10 0.66 0.64 39.44 37.62 95.39 59.16 59.75 101.5
Maltose 10 0.70 0.63 39.44 40.19 101.95 9 .16 58.97 99.68
2-nitrophenol 10 Out of scale 0.64 — — — 59.16 60.02 101.4
10 .80 — 39.44 46.61 118 — — —
Phenol
10 Out of scale 0.60 — — — 59.16 54.28 91.75
1— 0 .62 — — — 59.16 57.88 97.84
Pyrogallol 10 1.68 0.34 39.44 106.6 270 59.16 13.66 23.10
Resorcinol 10 Out of scale 0.57 — — — 59.16 48.81 82.50
Pyrocatechol 10 Out of scale 0.55 — — — 59.16 46.47 78.55
11 .09 0.75 39.44 66.68 169 59.16 76.94 130.0
Table 3. Eﬀect of common tolerances that may be present in the urine sample with LD using copper tetramine complex and 4-AAP.
[LD] = 2 ×10−4 M, [tolerance] = 2 ×10−4 M, [Cu+2] = 0.1M, [4-AAP] = 0.0295M, pH = 10.5, t = 10minutes, λ = 525nm.
Tolerant added Fold Taken (µg\mL) Found (µg\mL) Recovery %
—— 3 9 .44 — 100
Urea
13 9 .22 99.44
10 39.44 38.34 97.21
Salicylic acid 13 9 .22 99.44
10 39.44 44.47 112.7
Paracetamol
16 4 .09 162.5
10 39.44 Out of scale —
Ascorbic acid
13 6 .93 93.64
10 39.44 No absorbance —
Urea + salicylic acid 1 39.44 37.96 96.25
Table 4. Microdetermination of LD in pharmaceutical form using copper (II) complex and 4-AAP and LD with I
−
3 .
Drug Procedure (I) (µg\mL)
SD∗ CV∗ Error# %
Procedure (II) (µg\mL)
SD∗ CV∗ Error# %
Taken Found Taken Found
Levocar 35.01 36.02 0.65 1.83 7 .51 38.34 0.74 1.9
45.01 46.12 0.55 1.10 45.00 44.903 0.65 1.25
50.00 51.94 0.45 0.87 50.00 49.24 0.19 0.39
4.39 0.91
∗Number of replicates are 3–5.
#Average error.
of dopamine secretion that can be more easily detected
in urine than in plasma. The type of medication in
these cases depends on decreasing dopamine secretion by
blocking dopamine receptors in the brain using haloperi-
dol, Neurazine, Medicate, Promacide and Tegretol-T, for
example. From Table 5 it is obvious that there are three
urine samples which were collected from each of the
ﬁvepermanentlyschizophrenicpatientundermedication.
TheconcentrationofLDinurinesamplescollectedbefore
and after one and two hours from drug administration
nearly reachednormalvaluesinthecaseof patients1,2,3,
and4whencomparedtonormalpeople(32–36µgm L −1).
It can also be concluded that the type of medication
in these cases is highly eﬀective and can be continued.8 F. A. Nour El-Dien et al 2005:1 (2005)
Table 5. Determination of LD in the urine samples of schizophrenic patients using copper (II) complex and 4-AAP under selected
and optimum pH, temperature, time, and wavelength.
Patients Age (years) History
Medication Concentration
of LD in Urine
Name Dose (µg/mL)
1M a l e 41
Chronic schizophrenia
for 20 years. Began his
treatment 2 months ago.
Halloperidol
(tablet)
15mg/d
(5mg every 8 hours)
∗ 30.79
∗∗ 28.26
∗∗∗ 21.50
2 Males 58
Residual schizophrenia
for 25 years
Neurazine
(tablet)
100mg/d
(one tablet per day)
∗ 29.42
∗∗ 18.46
∗∗∗ 27.83
3 Males 52
Chronic schizophrenia
for 20 years
Modicate
(ampoules)
Millerile
(tablet)
25mg
(every two weeks)
200mg
(two doses daily)
∗ 39.13
∗∗ 34.45
∗∗∗ 16.78
4 Males 46
Residual schizophrenia
for 16 years
Neurazine
(tablet)
Saﬁnase
(tablet)
100mg
(two doses daily)
5mg
(two doses daily)
∗ 27.86
∗∗ 34.47
∗∗∗ 42.82
5 Males 49
Residual Schizophrenia
for 25 years
Modicate
(ampoules)
Promacide
(tablet)
Tegretol
(tablet)
25mg
(every two weeks)
100mg
(two doses daily)
200mg
(two doses daily)
∗ 106.08
∗∗ 98.77
∗∗∗ 79.51
∗ Before drug administration.
∗∗ One hour after drug administration.
∗∗∗Two hours after drug administration.
In Table 4, it is observed that there is an exception in the
case of patient 5, where the concentrations of LD in urine
one hour and two hours before and after drug adminis-
tration are 106,98.8, and 79.5µgm L −1,r e s p e c t i v e l y .T h i s
indicates that there is no responsiveness of patient 5 to
the type of medication, which must be changed or rear-
ranged. On discussing this point with a physician, he rep-
resented his agreement with our notes that patient 5 had
not improved as expected and the medication must be re-
arranged to decrease the concentration of LD to bring it
as close as possible to the normal value.
On comparison of the results obtained by the pro-
posed methods, (I) and (II), with those obtained by the
pharmaceutical method [19] using the t test for accu-
racy and F test for precision [20], the calculated val-
ues did not exceed the corresponding theoretical values
(tabulated values of t and F tests under conﬁdence limit
95% = 2.62–2.776 and 6.58–6.78, respectively) indicat-
ing insigniﬁcant diﬀerences between the results and also
referring to the robustness of the proposed procedures.
The proposed procedures are more accurate and of high
robustness, with high recoveries amounting to 98.70–
99.66 ± 0.6% compared with 99.6t o9 9 .9 ± 1.6% of the
pharmaceutical method.
CONCLUSION
The methods proposed for the estimation of LD
and CD are advantageous over many reported meth-
ods. This may be attributed to their sensitivity, rapidity,
noninterference with other ingredients usually present in
pharmaceuticalpreparationsandurinesamples,precision
andgoodagreementwiththeoﬃcialmethod.Hencethese
two methods can be used for the routine analyses.
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